Press Releases Year None202320222021202020192018201720162015201420132012 March 20, 2023 RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit March 9, 2023 Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update March 6, 2023 RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D. March 2, 2023 Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023 February 22, 2023 Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications February 8, 2023 Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss
March 20, 2023 RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit
March 9, 2023 Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 6, 2023 RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D.
March 2, 2023 Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023
February 22, 2023 Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
February 8, 2023 Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss